Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Rebersek Martina"'
Autor:
Hribernik Nezka, Strasek Katja, Huff Daniel T, Studen Andrej, Zevnik Katarina, Skalic Katja, Jeraj Robert, Rebersek Martina
Publikováno v:
Radiology and Oncology, Vol 58, Iss 3, Pp 335-347 (2024)
To evaluate the role of the novel quantitative imaging biomarker (QIB) SUVX% of 18F-FDG uptake extracted from early 18F-FDG-PET/CT scan at 4 weeks for the detection of immune-related adverse events (rAE) in a cohort of patients with metastatic melano
Externí odkaz:
https://doaj.org/article/5cb0fd0998244041889b09d3753cbc0e
Autor:
Rebersek Martina, Hribernik Nezka, Markovic Katarina, Markovic Stefan, Valentinuzzi Katja Ursic, Cemazar Maja, Zuliani Tea, Milacic Radmila, Scancar Janez
Publikováno v:
Radiology and Oncology, Vol 58, Iss 2, Pp 300-310 (2024)
Biliary tract cancers (BTCs) are usually diagnosed at an advanced stage, when the disease is incurable. Currently used tumor biomarkers have limited diagnostic value for BTCs, so there is an urgent need for sensitive and specific biomarkers for their
Externí odkaz:
https://doaj.org/article/5e2daa5a2df947359863565b212ac641
Publikováno v:
Radiology and Oncology, Vol 57, Iss 1, Pp 103-110 (2023)
We preformed a Phase IV non-interventional study to assess KRAS, NRAS and BRAF status in metastatic colorectal cancer (mCRC) patients suitable for 1st line treatment and to evaluate the decisions for 1st line treatment considering the treatment goals
Externí odkaz:
https://doaj.org/article/994aebd1ea284397a3baf7b4d27035c7
Autor:
Rebersek Martina
Publikováno v:
Radiology and Oncology, Vol 54, Iss 3, Pp 272-277 (2020)
Colorectal cancer (CRC) is one of the most common types of cancer in the world. Metastatic disease is still incurable in most of these patients, but the survival rate has improved by treatment with novel systemic chemotherapy and targeted therapy in
Externí odkaz:
https://doaj.org/article/1837c7f4fbea4146894ef1747bdd5e5d
Autor:
Hribernik Nezka, Boc Marko, Ocvirk Janja, Knez-Arbeiter Jasna, Mesti Tanja, Ignjatovic Marija, Rebersek Martina
Publikováno v:
Radiology and Oncology, Vol 54, Iss 1, Pp 119-127 (2020)
Based on recent data from clinical trials, the immune checkpoint inhibitor pembrolizumab prolongs survival and has a good toxicity profile in patients with advanced or metastatic melanoma. However, the question remains whether these results are trans
Externí odkaz:
https://doaj.org/article/4d387ba83ed248a1a9d60068708a81d9
Publikováno v:
Radiology and Oncology, Vol 53, Iss 1, Pp 85-95 (2019)
Histological parameters of primary tumour and nodal metastases are prognostic factors for survival of operable colorectal (CRC) patients, but not predictive for response rate of systemic therapy. KRAS mutations in codons 12 and 13 were first recogniz
Externí odkaz:
https://doaj.org/article/bc66407f0ec24731b6ac36a6000ebbd8
Autor:
Moltara Maja Ebert, Novakovic Srdjan, Boc Marko, Bucic Marina, Rebersek Martina, Zadnik Vesna, Ocvirk Janja
Publikováno v:
Radiology and Oncology, Vol 52, Iss 3, Pp 289-295 (2018)
BRAF, NRAS and c-KIT mutations are characteristics of tumour tissues that influence on treatment decisions in metastatic melanoma patients. Mutation frequency and their correlation with histological characteristics in Slovenian population have not be
Externí odkaz:
https://doaj.org/article/0f1e37e3af614d74b759208309c43749
Autor:
Ocvirk Janja, Moltara Maja Ebert, Mesti Tanja, Boc Marko, Rebersek Martina, Volk Neva, Benedik Jernej, Hlebanja Zvezdana
Publikováno v:
Radiology and Oncology, Vol 50, Iss 2, Pp 226-231 (2016)
Metastatic colorectal cancer (mCRC) is mainly a disease of elderly, however, geriatric population is underrepresented in clinical trials. Patient registries represent a tool to assess and follow treatment outcomes in this patient population. The aim
Externí odkaz:
https://doaj.org/article/65a76550d7cd441a89b2b857aadf5433
Publikováno v:
Radiology and Oncology, Vol 49, Iss 1, Pp 80-85 (2015)
Background. Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial. Patients and methods. The medic
Externí odkaz:
https://doaj.org/article/00c32a6d456149d790fee065bc4a7cd2
Publikováno v:
BMC Cancer, Vol 9, Iss 1, p 120 (2009)
Abstract Background Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC). There are, however, no data about the use of the XELIRI regimen in the neoadjuv
Externí odkaz:
https://doaj.org/article/221126637cb0412cbaa44c56db826d7e